Original Article
Combined treatment of inetetamab plus pyrotinib and vinorelbine in managing advanced HER2-positive breast cancer patients (ILLUMINE): a multicenter, retrospective, real-world study
Translational Breast Cancer Research
2025;
6:
31
.
(30 October 2025)
Case Report
Multimodality evaluation and ultrasound-guided aspiration of a biopsy-proven inspissated clogged milk duct: a case report
Translational Breast Cancer Research
2025;
6:
30
.
(30 July 2025)
Editorial Commentary
Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04
Translational Breast Cancer Research
2025;
6:
29
.
(30 July 2025)
Editorial Commentary
DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer
Translational Breast Cancer Research
2025;
6:
28
.
(30 July 2025)
Editorial Commentary
Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future?
Translational Breast Cancer Research
2025;
6:
27
.
(30 July 2025)
Editorial Commentary
Key breast cancer highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Translational Breast Cancer Research
2025;
6:
26
.
(30 July 2025)
Mini-Review
Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab
Translational Breast Cancer Research
2025;
6:
25
.
(30 July 2025)
Review Article
Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies
Translational Breast Cancer Research
2025;
6:
24
.
(30 July 2025)
Review Article
Escalation and optimisation of primary breast cancer treatment with antibody-drug conjugates
Translational Breast Cancer Research
2025;
6:
23
.
(30 July 2025)
Original Article
Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses
Translational Breast Cancer Research
2025;
6:
22
.
(30 July 2025)
Expert Consensus
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2
Translational Breast Cancer Research
2025;
6:
21
.
(30 July 2025)
Review Article
The role of a national cancer registry in effective implementation and monitoring of the Global Breast Cancer Initiative (GBCI) framework in Ghana: a narrative review
Translational Breast Cancer Research
2025;
6:
20
.
(30 April 2025)
Review Article
Non-commonly prescribed physical exercises, disciplines and sports in breast cancer survivors: a narrative review
Translational Breast Cancer Research
2025;
6:
19
.
(30 April 2025)
Review Article
Radiotherapy in breast cancer patients achieving nodal pathologic complete response after neoadjuvant therapy: a scoping review
Translational Breast Cancer Research
2025;
6:
18
.
(30 April 2025)
Review Article
Preoperative partial breast radiation for favorable early-stage breast cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
17
.
(30 April 2025)
Review Article
Breast cancer screening for transgender individuals with breast cancer susceptibility genes
Translational Breast Cancer Research
2025;
6:
16
.
(30 April 2025)
Review Article
Contrast-enhanced mammography in high-dense breasts: a narrative review
Translational Breast Cancer Research
2025;
6:
15
.
(30 April 2025)
Review Article
De-escalation of axillary interventions in the management of breast cancer patients following neoadjuvant systemic treatment
Translational Breast Cancer Research
2025;
6:
14
.
(30 April 2025)
Review Article
Omission of breast surgery in exceptional responders after neoadjuvant chemotherapy—what are future possibilities?—a narrative review
Translational Breast Cancer Research
2025;
6:
13
.
(30 April 2025)
Original Article
Enhancing patient education in breast surgery: artificial intelligence-powered guidance for mastopexy, augmentation, reduction, and reconstruction
Translational Breast Cancer Research
2025;
6:
12
.
(30 April 2025)
Editorial Commentary
DESTINY-Breast06 continues to explore HR+, HER2-negative metastatic breast cancer beyond DESTINY-Breast04
Translational Breast Cancer Research
2025;
6:
11
.
(24 January 2025)
Editorial Commentary
Understanding the NATALEE trial—from a methodologist stand of point
Translational Breast Cancer Research
2025;
6:
10
.
(24 January 2025)
Review Article
Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
9
.
(24 January 2025)
Review Article
Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
8
.
(24 January 2025)
Review Article
Neurological symptom management in breast cancer meningeal carcinomatosis
Translational Breast Cancer Research
2025;
6:
7
.
(24 January 2025)